Johnson & Johnson vs. Relmada Therapeutics, Inc. Common Stock
Johnson & Johnson and Relmada Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| JNJ | RLMD | |
|---|---|---|
| Market Cap | $658.00 billion | $488.55 million |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | — |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| JNJ | RLMD | |
|---|---|---|
| P/E Ratio | 31.66 | — |
| Price / Book | 7.74 | — |
| Price / Sales | 6.72 | — |
JNJ and RLMD split the valuation factors evenly.
Profitability
| JNJ | RLMD | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | — |
JNJ and RLMD split the profitability factors evenly.
Dividend
| JNJ | RLMD | |
|---|---|---|
| Dividend Yield | 1.96% | — |
| Payout Ratio | 62.18 | — |
JNJ and RLMD split the dividend factors evenly.
Risk & Sentiment
| JNJ | RLMD | |
|---|---|---|
| Short Interest | 0.67% | 0.00% |
RLMD leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, RLMD overview, RLMD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.